{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:07:25Z","timestamp":1783408045083,"version":"3.54.6"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Pfizer SLU"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40261-021-01086-7","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T11:02:22Z","timestamp":1636196542000},"page":"1055-1066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9633-0888","authenticated-orcid":false,"given":"Narc\u00eds","family":"Cardoner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-293X","authenticated-orcid":false,"given":"Antoni","family":"Sicras-Mainar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7987-360X","authenticated-orcid":false,"given":"Javier","family":"Rejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-3090","authenticated-orcid":false,"given":"Beatriz","family":"Armada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"1086_CR1","unstructured":"World Health Organization. Depression and Other Common Mental Disorders Global Health Estimates. 2017."},{"key":"1086_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1741-7015-9-90","volume":"9","author":"E Bromet","year":"2011","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.","journal-title":"BMC Med"},{"key":"1086_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/aje\/kwp037","volume":"169","author":"J Wang","year":"2009","unstructured":"Wang J, Schmitz N, Dewa C, Stansfeld S. Changes in perceived job strain and the risk of major depression: results from a population-based longitudinal study. Am J Epidemiol. 2009;169:1085\u201391.","journal-title":"Am J Epidemiol"},{"key":"1086_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJMra1201534","volume":"369","author":"CJL Murray","year":"2013","unstructured":"Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448\u201357.","journal-title":"N Engl J Med"},{"key":"1086_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/09638280600835267","volume":"29","author":"R Crisp","year":"2007","unstructured":"Crisp R. Depression and occupational disability in five diagnostic groups: a review of recent research. Disabil Rehabil. 2007;29:267\u201379.","journal-title":"Disabil Rehabil"},{"key":"1086_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4088\/JCP.v60n0302","volume":"60","author":"ML Crismon","year":"1999","unstructured":"Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, et al. The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry. 1999;60:142\u201356.","journal-title":"J Clin Psychiatry"},{"key":"1086_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1086_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jad.2016.02.012","volume":"196","author":"GA Bushnell","year":"2016","unstructured":"Bushnell GA, St\u00fcrmer T, White A, Pate V, Swanson SA, Azrael D, et al. Predicting persistence to antidepressant treatment in administrative claims data: considering the influence of refill delays and prior persistence on other medications. J Affect Disord. 2016;196:138\u201347.","journal-title":"J Affect Disord"},{"issue":"Suppl 2","key":"1086_CR9","first-page":"34","volume":"62","author":"K Demyttenaere","year":"2001","unstructured":"Demyttenaere K, Enzlin P, Dew\u00e9 W, Boulanger B, De Bie J, De Troyer W, et al. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J Clin Psychiatry. 2001;62(Suppl 2):34\u20137.","journal-title":"J Clin Psychiatry"},{"key":"1086_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2165\/00023210-200822110-00005","volume":"22","author":"DV Sheehan","year":"2008","unstructured":"Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ. Differences in medication adherence and healthcare resource utilization patterns. CNS Drugs. 2008;22:963\u201373.","journal-title":"CNS Drugs"},{"key":"1086_CR11","volume-title":"National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults","author":"British Psychological Society","year":"2010","unstructured":"British Psychological Society. National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults. Updated. Leicester: British Psychological Society; 2010.","edition":"Updated"},{"key":"1086_CR12","volume-title":"Adherece to long term therapies: evidence for action","author":"WHO","year":"2003","unstructured":"WHO. Adherece to long term therapies: evidence for action. Geneva: WHO; 2003."},{"key":"1086_CR13","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.4088\/JCP.14m09531","volume":"77","author":"A Krivoy","year":"2016","unstructured":"Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G, Weizman A, et al. Adherence to antidepressants is associated with lower mortality. J Clin Psychiatry. 2016;77:e566\u201372.","journal-title":"J Clin Psychiatry"},{"key":"1086_CR14","first-page":"91","volume":"42","author":"M Serrano","year":"2014","unstructured":"Serrano M, Vives M, Mateu C, Vicens C, Molina R, Puebla-Guedea M, et al. Adherencia terap\u00e9utica en pacientes depresivos de atenci\u00f3n primaria: un estudio longitudinal. Actas Espanolas de Psiquiatria. 2014;42:91\u20138.","journal-title":"Actas Espanolas de Psiquiatria."},{"key":"1086_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archpsyc.55.12.1128","volume":"55","author":"CA Melfi","year":"1998","unstructured":"Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128.","journal-title":"Arch Gen Psychiatry"},{"key":"1086_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gaceta.2009.05.012","volume":"24","author":"A Sicras-Mainar","year":"2010","unstructured":"Sicras-Mainar A, Blanca-Tamayo M, Guti\u00e9rrez-Nicuesa L, Salvatella-Pasant J, Navarro-Artieda R. Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisi\u00f3n de la depresi\u00f3n mayor en Espa\u00f1a: estudio longitudinal de \u00e1mbito poblacional. Gac Sanit. 2010;24:13\u20139.","journal-title":"Gac Sanit"},{"key":"1086_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.157.1.1","volume":"157","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157:1\u201345.","journal-title":"Am J Psychiatry"},{"key":"1086_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2045125312445469","volume":"2","author":"E Penn","year":"2012","unstructured":"Penn E, Tracy DK. The drugs don\u2019t work? Antidepressants and the current and future pharmacological management of depression. Therap Adv Psychopharmacol. 2012;2:179\u201388.","journal-title":"Therap Adv Psychopharmacol."},{"key":"1086_CR19","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de utilizaci\u00f3n de medicamentos 14012015 de la AEMPS sobre Utilizaci\u00f3n de medicamentos antidepresivos en Espa\u00f1a durante el periodo 2000-2013. Ref. U\/AD\/V1\/14012015. 2015;1\u20134."},{"key":"1086_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.psiq.2013.06.001","volume":"20","author":"N Cardoner","year":"2013","unstructured":"Cardoner N. Desvenlafaxine, a new SNRI for the treatment of major depression: a literature review. Psiquiatr\u00eda Biol\u00f3gica. 2013;20:2\u20137.","journal-title":"Psiquiatr\u00eda Biol\u00f3gica."},{"key":"1086_CR21","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.2147\/NDT.S115094","volume":"12","author":"C Solem","year":"2016","unstructured":"Solem C, Shelbaya A, Wan Y, Deshpande C, Alvir J, Pappadopulos E. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. Neuropsychiatr Dis Treat. 2016;12:2755\u201364.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1086_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/NDT.S157708","volume":"14","author":"Y Low","year":"2018","unstructured":"Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567\u201380.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1086_CR23","doi-asserted-by":"publisher","first-page":"e90453","DOI":"10.1371\/journal.pone.0090453","volume":"9","author":"A Sicras-Mainar","year":"2014","unstructured":"Sicras-Mainar A, Guijarro P, Armada B, Blanca-Tamayo M, Navarro-Artieda R. Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. de Castro F, editor. PLoS ONE. 2014;9:e90453.","journal-title":"PLoS ONE"},{"key":"1086_CR24","volume-title":"CIE 10: Trastornos mentales y del comportamiento: descripciones cl\u00ednicas y pautas para el diagn\u00f3stico","author":"WHO","year":"1992","unstructured":"WHO. CIE 10: Trastornos mentales y del comportamiento: descripciones cl\u00ednicas y pautas para el diagn\u00f3stico. Geneva: WHO; 1992."},{"key":"1086_CR25","unstructured":"Guy William, (U.S.). NI of MH, Branch. PR, Program. ECDE. ECDEU assessment manual for psychopharmacology. Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"1086_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2013","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. New York: Wiley; 2013."},{"key":"1086_CR27","volume-title":"Interventions for helping patients to follow prescriptions for medications. Cochrane database of systematic reviews","author":"R Haynes","year":"2002","unstructured":"Haynes R, McDonald H, Garg A, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane database of systematic reviews. Chichester: Wiley; 2002."},{"key":"1086_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-199501000-00006","volume":"33","author":"EHB Lin","year":"1995","unstructured":"Lin EHB, Von KM, Katon W, Bush T, Simon GE, Walker E, et al. The role of the primary care physician in patients\u02bc adherence to antidepressant therapy. Med Care. 1995;33:67\u201374.","journal-title":"Med Care"},{"key":"1086_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1034\/j.1600-0447.2002.1r084.x","volume":"105","author":"R Lingam","year":"2002","unstructured":"Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164\u201372.","journal-title":"Acta Psychiatr Scand"},{"key":"1086_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101\u20138.","journal-title":"Am J Psychiatry"},{"key":"1086_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/CEOR.S17846","volume":"3","author":"Y Chen","year":"2011","unstructured":"Chen Y, Liu F. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. ClinicoEconomics Outcomes Res. 2011;3:63.","journal-title":"ClinicoEconomics Outcomes Res."},{"key":"1086_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4236\/ojpsych.2012.24038","volume":"02","author":"S Dav\u00e9","year":"2012","unstructured":"Dav\u00e9 S, Classi P, Le Kim T, Maguire A, Ball S. Discontinuation of antidepressant therapy among patients with major depressive disorder. Open J Psychiatry. 2012;02:272\u201380.","journal-title":"Open J Psychiatry."},{"key":"1086_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.aprim.2013.11.003","volume":"46","author":"I P\u00e1rraga Mart\u00ednez","year":"2014","unstructured":"P\u00e1rraga Mart\u00ednez I, L\u00f3pez-Torres Hidalgo J, del Campo del campo JM, Villena Ferrer A, Morena Rayo S, Escobar RF. Seguimiento de la adherencia al tratamiento antidepresivo en pacientes que inician su consumo. Atenci\u00f3n Primaria. 2014;46:357\u201366.","journal-title":"Atenci\u00f3n Primaria."},{"key":"1086_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/01.mlr.0000204287.82701.9b","volume":"44","author":"CR Cantrell","year":"2006","unstructured":"Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy. Med Care. 2006;44:300\u20133.","journal-title":"Med Care"},{"key":"1086_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-017-0417-0","volume":"31","author":"KR Keyloun","year":"2017","unstructured":"Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD). CNS Drugs. 2017;31:421\u201332.","journal-title":"CNS Drugs"},{"key":"1086_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/YIC.0b013e3283611d03","volume":"13","author":"K Tourian","year":"2013","unstructured":"Tourian K, Wang Y, Ii Y. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol. 2013;13:1.","journal-title":"Int Clin Psychopharmacol"},{"key":"1086_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9:17.","journal-title":"Syst Rev"},{"issue":"3","key":"1086_CR38","first-page":"PCC.09r00845","volume":"12","author":"MR Liebowitz","year":"2010","unstructured":"Liebowitz MR, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09r00845.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"1086_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-244X-13-94","volume":"13","author":"MR Liebowitz","year":"2013","unstructured":"Liebowitz MR, Tourian KA, Hwang E, Mele L. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg\/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013;13:94.","journal-title":"BMC Psychiatry"},{"key":"1086_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/YIC.0b013e32830263de","volume":"23","author":"DZ Lieberman","year":"2008","unstructured":"Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23:188\u201397.","journal-title":"Int Clin Psychopharmacol"},{"key":"1086_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YIC.0b013e32830cebed","volume":"23","author":"P Boyer","year":"2008","unstructured":"Boyer P, Montgomery S, Lepola U, Germain J-M, Brisard C, Ganguly R, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg\/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243\u201353.","journal-title":"Int Clin Psychopharmacol"},{"key":"1086_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","volume":"26","author":"E Spina","year":"2012","unstructured":"Spina E, Trifir\u00f2 G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39\u201367.","journal-title":"CNS Drugs"},{"key":"1086_CR43","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1517\/17425255.2010.535810","volume":"6","author":"AI Nichols","year":"2010","unstructured":"Nichols AI, Tourian KA, Tse SY, Paul J. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin\u2013norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol. 2010;6:1565\u201374.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1086_CR44","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1586\/14737175.8.12.1787","volume":"8","author":"J Kamath","year":"2008","unstructured":"Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurotherap. 2008;8:1787\u201397.","journal-title":"Expert Rev Neurotherap."},{"issue":"2","key":"1086_CR45","doi-asserted-by":"publisher","first-page":"10.4088\/PCC.14r","DOI":"10.4088\/PCC.14r01710","volume":"17","author":"M Macaluso","year":"2015","unstructured":"Macaluso M, Nichols AI, Preskorn SH. How the probability and potential clinical significance of pharmacokinetically mediated drug-drug interactions are assessed in drug development. Primary Care Companion CNS Disord. 2015:17(2). https:\/\/doi.org\/10.4088\/PCC.14r01710","journal-title":"Primary Care Companion CNS Disord."},{"key":"1086_CR46","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/jcm8050719","volume":"8","author":"AL Montejo","year":"2019","unstructured":"Montejo AL, Becker J, Bueno G, Fern\u00e1ndez-Ovejero R, Gallego MT, Gonz\u00e1lez N, et al. Frequency of sexual dysfunction in patients treated with desvenlafaxine: a prospective naturalistic study. J Clin Med. 2019;8:715.","journal-title":"J Clin Med"},{"key":"1086_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/107755870005700405","volume":"57","author":"M Tai-Seale","year":"2000","unstructured":"Tai-Seale M, Croghan TW, Obenchain R. Determinants of antidepressant treatment compliance: implications for policy. Med Care Res Rev. 2000;57:491\u2013512.","journal-title":"Med Care Res Rev"},{"key":"1086_CR48","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357\u201366.","journal-title":"Lancet"},{"key":"1086_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"1086_CR50","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"1086_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691\u2013705.","journal-title":"Br J Clin Pharmacol"},{"key":"1086_CR52","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/bmjqs-2017-007453","volume":"27","author":"P Mongkhon","year":"2018","unstructured":"Mongkhon P, Ashcroft DM, Scholfield CN, Kongkaew C. Hospital admissions associated with medication non-adherence: a systematic review of prospective observational studies. BMJ Qual Saf. 2018;27:902\u201314.","journal-title":"BMJ Qual Saf"},{"key":"1086_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.rpsm.2015.08.002","volume":"9","author":"J Rejas Guti\u00e9rrez","year":"2016","unstructured":"Rejas Guti\u00e9rrez J, Blanca Tamayo M, Gasc\u00f3n Barrachina J, Armada PB. Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain. Revista de Psiquiatr\u00eda y Salud Mental. 2016;9:87\u201396.","journal-title":"Revista de Psiquiatr\u00eda y Salud Mental."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01086-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01086-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01086-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T18:00:40Z","timestamp":1675879240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01086-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01086-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"26 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded Pfizer SLU.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Narc\u00eds Cardoner has received personal fees from Elsevier, Exeltis, Janssen, Lundbeck, Pfizer, Servier, Recercaixa, the Spanish Ministry of Health, the Spanish Ministry of Science and Innovation (CIBERSAM) & Health Research and Innovation Strategic Plan (PERIS) 2016-2020. Antoni Sicras-Mainar has no conflict of interest to declare. Javier Rejas reports to work in the Health Economics and Outcomes Research department of Pfizer SLU. Beatriz Armada reports to work in the medical department of Pfizer SLU.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The study was approved by the Clinical Research Ethics Committee of the Parc Taul\u00ed University Hospital in Sabadell and classified by the Spanish Drug Agency (AEMPS) in accordance with current regulations, under the study code: PFI-DES-2016-01.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was exempted from informed consent, due to its retrospective design and under current regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data confidentiality is warranted in accordance with the Organic Law 15\/1999 of December 13 on the Protection of Personal Data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Statistical analysis was performed with the SAS statistical software v9.2 (SAS Institute Inc., Cary, NC, USA).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NC coordinated the study and NC, JR and BA contributed to the design of the study. All authors participated in the data analysis and interpretation of the results. All authors drafted, revised, and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}